Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label mogamulizumab in previously treated CCR4-positive PTCL
NL-OMON39990Phase 2Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab in peripheral T-cell lymphoma (PTCL), sponsored by Kyowa Kirin. Primary endpoint: overall response rate. Started Dec 2012; status: active, not recruiting.
02
Drugs
mogamulizumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NL-OMON39990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39990.